original ) (raw )Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
Zahi Touma
Rheumatology and Therapy, 2020
View PDFchevron_right
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Yoshiya Tanaka
Annals of the rheumatic diseases, 2018
View PDFchevron_right
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
Stefan Detchev
RMD Open, 2021
View PDFchevron_right
Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a Phase 3 randomized placebo-controlled trial
Stefan Detchev
Modern rheumatology, 2018
View PDFchevron_right
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study
Marcello Govoni
Journal of Autoimmunity, 2017
View PDFchevron_right
Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
Zahi Touma
Patient Related Outcome Measures, 2019
View PDFchevron_right
Belimumab in the treatment of systemic lupus erythematous: An evidence based review of its place in therapy
Frederico Marcondes
Autoimmunity Reviews, 2018
View PDFchevron_right
Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
Sarowar Golam
Journal of Comparative Effectiveness Research
View PDFchevron_right
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus
William Stohl
The Journal of Rheumatology, 2014
View PDFchevron_right
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Frederico Marcondes
Annals of the Rheumatic Diseases, 2012
View PDFchevron_right
Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Giuseppe Turchetti
BioMed Research International, 2014
View PDFchevron_right
Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study
William Stohl
Arthritis & rheumatology (Hoboken, N.J.), 2017
View PDFchevron_right
Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider
Giuseppe Turchetti
Clinical and experimental rheumatology
View PDFchevron_right
Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
Kyriakos Kirou
Frontiers in Immunology
View PDFchevron_right
Economic Evaluations in Systemic Lupus Erythematosus
Gerardo echeverri quintana
View PDFchevron_right
Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients
Micol Frassi
The Israel Medical Association journal : IMAJ, 2014
View PDFchevron_right
Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study
Mehdi Zakerifar
Lupus Science & Medicine
View PDFchevron_right
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study
Evangelos Theotikos
Frontiers in Immunology, 2023
View PDFchevron_right
Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis
Shakar Bhandari
2021
View PDFchevron_right
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
Katerina Chatzidionysiou
Rheumatology, 2019
View PDFchevron_right
Systemic Lupus Erythematosus in Saudi Arabia: morbidity and mortality in a multiethnic population
سامي محمد عبدالله بحلس
Lupus, 2007
View PDFchevron_right
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
Amber Martin
Lupus science & medicine, 2023
View PDFchevron_right
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
William Freimuth
Lupus science & medicine, 2014
View PDFchevron_right
Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
Andrew Chow
Rheumatology International, 2017
View PDFchevron_right